
Article 1 
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.
Article 2 
In Regulation (EU) 2017/776, the second subparagraph of Article 2(2) is replaced by the following:
'In the Annex, point (1), point (2) and points (a), (b) and (c) of point (3) shall apply from 1 June 2017.'
Article 3 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Point (1) and point (a) of point (2) of the Annex shall apply from 1 December 2019.
Points (b), (c), (d) and (e) of point (2) of the Annex shall apply from 1 May 2020.
By way of derogation from the third paragraph of this Article, substances and mixtures may, before 1 May 2020, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 4 October 2018.
For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

((1)) in Part 1, the heading of point 1.1.1.4 is replaced by the following:
'Chemical name';
((2)) in Part 3, Table 3.1 is amended as follows:

((a)) the title of the second column is replaced by the following: ‘Chemical name’;
((b)) the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)

(*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;
((c)) the entry corresponding to index number 607-414-00-6 is deleted;
((d)) the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:

Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘006-044-00-7 isoproturon (ISO);3-(4-isopropylphenyl)-1,1-dimethylurea 251-835-4 34123-59-6 Carc. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H351H373 (blood)H400H410 GHS08GHS09Wng H351H373 (blood)H410  M = 10M = 10’ 
‘015-101-00-5 phosmet (ISO);S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;O,O-dimethyl-S-phthalimidomethyl phosphorodithioate 211-987-4 732-11-6 Repr. 2Acute Tox. 4Acute Tox. 3STOT SE 1Aquatic Acute 1Aquatic Chronic 1 H361fH332H301H370 (nervous system)H400H410 GHS08GHS06GHS09Dgr H361fH332H301H370 (nervous system)H410  M = 100M = 100’ 
‘016-096-00-2 thifensulfuron-methyl (ISO);methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate — 79277-27-3 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 100M = 100’ 
‘017-011-00-1 sodium hypochlorite, solution … % Cl active 231-668-3 7681-52-9 Skin Corr. 1BEye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H314H318H400H410 GHS05GHS09Dgr H314H410 EUH031 M = 10M = 1EUH031:C ≥ 5 % B’
‘025-002-00-9 potassium permanganate 231-760-3 7722-64-7 Ox. Sol. 2Repr. 2Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 H272H361dH302H400H410 GHS03GHS08GHS07GHS09Dgr H272H361dH302H410’   
‘603-180-00-4 colecalciferol;cholecalciferol;vitamin D3 200-673-2 67-97-0 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2STOT RE 1 H330H310H300H372 GHS06GHS08Dgr H330H310H300H372  
 inhalation:
ATE = 0,05 mg/L (dusts or mists)
 dermal:
ATE = 50 mg/kg bw
 oral:
ATE = 35 mg/kg bw
STOT RE 1; H372: C ≥ 3 %
STOT RE 2; H373: 0,3 % ≤ C < 3 %’ 
‘604-014-00-3 chlorocresol;4-chloro-m-cresol;4-chloro-3-methylphenol 200-431-6 59-50-7 Acute Tox. 4Skin Corr. 1CEye Dam. 1STOT SE 3Skin Sens. 1B Aquatic Acute 1Aquatic Chronic 3 H302H314H318H335H317H400H412 GHS07GHS05GHS09Dgr H302H314H335H317H410  M = 1’ 
‘604-016-00-4 1,2-dihydroxybenzene;pyrocatechol 204-427-5 120-80-9 Carc. 1ΒMuta. 2Acute Tox. 3Acute Tox. 3Skin Irrit. 2Eye Irrit. 2 H350H341H311H301H315H319 GHS08GHS06Dgr H350H341H311H301H315H319  
 oral:
ATE = 300 mg/kg bw
 dermal:
ATE = 600 mg/kg bw’ 
‘604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. 2Skin Irrit. 2Eye Dam. 1Aquatic Chronic 1 H361fH315H318H410 GHS08GHS05GHS09Dgr H361fH315H318H410  M = 1’ 
‘605-003-00-6 acetaldehyde;ethanal 200-836-8 75-07-0 Flam. Liq. 1Carc. 1BMuta. 2STOT SE 3Eye Irrit. 2 H224H350H341H335H319 GHS02GHS08GHS07Dgr H224H350H341H335H319’   
‘606-047-00-9 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone 404-360-3 119313-12-1 Repr. 1BAquatic Acute 1Aquatic Chronic 1 H360DH400H410 GHS08GHS09Dgr H360DH410’   
‘607-096-00-9 maleic anhydride 203-571-6 108-31-6 Acute Tox. 4STOT RE 1Skin Corr. 1BEye Dam. 1Resp. Sens. 1Skin Sens. 1A H302H372 (respiratory system) (inhalation)H314H318H334H317 GHS07GHS08GHS05Dgr H302H372 (respiratory system) (inhalation)H314H334H317 EUH071 Skin Sens. 1A; H317: C ≥ 0,001 %’ 
‘607-103-00-5 succinic anhydride 203-570-0 108-30-5 Acute Tox. 4Skin Corr. 1Eye Dam. 1Resp. Sens. 1Skin Sens. 1 H302H314H318H334H317 GHS07GHS05GHS08Dgr H302H314H334H317 EUH071’  
‘607-113-00-X isobutyl methacrylate 202-613-0 97-86-9 Flam. Liq. 3STOT SE 3Skin Irrit. 2Skin Sens. 1B H226H335H315H317 GHS02GHS07Wng H226H335H315H317   D’
‘607-373-00-4 quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate 414-200-4 200509-41-7 Carc. 2Repr. 2Acute Tox. 4STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H351H361fdH302H373H400H410 GHS08GHS07GHS09Wng H351H361fdH302H373H410  M = 1M = 1’ 
‘613-167-00-5 reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) — 55965-84-9 Acute Tox. 2Acute Tox. 2Acute Tox. 3Skin Corr. 1CEye Dam. 1Skin Sens. 1A Aquatic Acute 1Aquatic Chronic 1 H330H310H301H314H318H317H400H410 GHS06GHS05GHS09Dgr H330H310H301H314H317H410 EUH071 Skin Corr. 1C; H314: C ≥ 0,6 %Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %Eye Dam. 1; H318: C ≥ 0,6 %Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %Skin Sens. 1A; H317: C ≥ 0,0015 %M = 100M = 100 B’
‘613-205-00-0 propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole 262-104-4 60207-90-1 Repr. 1BAcute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H360DH302H317H400H410 GHS08GHS07GHS09Dgr H360DH302H317H410  M = 1M = 1’ 
‘614-001-00-4 nicotine (ISO);3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2Acute Tox. 2Acute Tox. 2Aquatic Chronic 2 H330H310H300H411 GHS06GHS09Dgr H330H310H300H411  
 inhalation:
ATE = 0,19 mg/L (dusts or mists)
 dermal:
ATE = 70 mg/kg bw
 oral:
ATE = 5 mg/kg bw’ 
((e)) the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:

Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘604-094-00-X isoeugenol; [1](E)-2-methoxy-4-(prop-1-enyl)phenol; [2](Z)-2-methoxy-4-(prop-1-enyl)phenol [3] 202-590-7 [1]227-678-2 [2]227-633-7 [3] 97-54-1 [1]5932-68-3 [2]5912-86-7 [3] Skin Sens. 1A H317 GHS07Wng H317  Skin Sens. 1A; H317: C ≥ 0,01 %’ 
‘607-724-00-1 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin — 240494-71-7 Acute Tox. 4Acute Tox. 3STOT SE 1STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H332H301H370 (nervous system)H373H400H410 GHS06GHS08GHS09Dgr H332H301H370 (nervous system)H373H410  M = 100M = 100’ 
‘607-725-00-7 isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene — 65733-16-6 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1’ 
‘607-726-00-2 pinoxaden (ISO);8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate — 243973-20-8 Repr. 2Acute Tox. 4Acute Tox. 4Eye Irrit. 2STOT SE 3Skin Sens. 1AAquatic Acute 1Aquatic Chronic 3 H361dH332H302H319H335H317H400H412 GHS08GHS07GHS09Wng H361dH332H302H319H335H317H410  
 inhalation:
ATE = 4,63 mg/L (dusts or mists)
 oral:
ATE = 500 mg/kg bw
M = 1’ 
‘607-727-00-8 tetramethrin (ISO);(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate 231-711-6 7696-12-0 Carc. 2Acute Tox. 4STOT SE 2Aquatic Acute 1Aquatic Chronic 1 H351H302H371 (nervous system) (inhalation)H400H410 GHS08GHS07GHS09Wng H351H302H371 (nervous system) (inhalation)H410  M = 100M = 100’ 
‘607-728-00-3 (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate 214-619-0 1166-46-7 Carc. 2Acute Tox. 4STOT SE 2Aquatic Acute 1Aquatic Chronic 1 H351H302H371 (nervous system) (inhalation)H400H410 GHS08GHS07GHS09Wng H351H302H371 (nervous system) (inhalation)H410  M = 100M = 100’ 
‘607-729-00-9 mesosulfuron-methyl (ISO);methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate; — 208465-21-8 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 100M = 100’ 
‘607-730-00-4 spirodiclofen (ISO);3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate — 148477-71-8 Carc. 1BRepr. 2STOT RE 2Skin Sens. 1BAquatic Chronic 1 H350H361fH373H317H410 GHS08GHS07GHS09Dgr H350H361fH373H317H410  M = 10’ 
‘607-731-00-X sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium 218-953-8 2302-17-2 Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H317H400H410 GHS07GHS09Wng H317H410  M = 1M = 1’ 
‘607-732-00-5 salicylic acid 200-712-3 69-72-7 Repr. 2Acute Tox. 4Eye Dam. 1 H361dH302H318 GHS08GHS07GHS05Dgr H361dH302H318’   
‘608-068-00-9 flutianil (ISO);(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile — 958647-10-4 Aquatic Chronic 1 H410 GHS09Wng H410  M = 100’ 
‘612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 - Repr. 2Acute Tox. 4Skin Corr. 1BEye Dam. 1 H361fH302H314H318 GHS08GHS07GHS05Dgr H361fH302H314 EUH071’  
‘613-326-00-9 2-methylisothiazol-3(2H)-one 220-239-6 2682-20-4 Acute Tox. 2Acute Tox. 3Acute Tox. 3Skin Corr. 1BEye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H330H311H301H314H318H317H400H410 GHS05GHS06GHS09Dgr H330H311H301H314H317H410 EUH071 Skin Sens. 1A; H317: C ≥ 0,0015 %M = 10M = 1’ 
‘613-327-00-4 pyroxsulam (ISO);N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide — 422556-08-9 Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H317H400H410 GHS07GHS09Wng H317H410  M = 100M = 100’ 
‘613-328-00-X 1-vinylimidazole 214-012-0 1072-63-5 Repr. 1B H360D GHS08Dgr H360D  Repr. 1B; H360D: C ≥ 0,03 %’ 
‘616-224-00-2 amisulbrom (ISO);3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide — 348635-87-0 Carc. 2Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H351H319H400H410 GHS08GHS07GHS09Wng H351H319H410  M = 10M = 10’ 
